Veloxis Pharmaceuticals announces financial results for the first three months of 2013

HORSHOLM, Denmark, May 15, 2013 /PRNewswire/ --

Highlights:

  • On 29 April, 2013 Veloxis submitted the MAA to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro™ for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission is based on the favorable results of the LCP-Tacro™ Phase III 3001 study in stable kidney transplant patients and data from an extensive Phase I and II clinical program. Veloxis expects the decision from the European Union in 2014.
  • Veloxis reported a net loss of DKK 35.7 million for the first quarter of 2013 compared to a net loss of DKK 75.0 million for the same period in 2012. The reported net loss is in line with expectations and the financial outlook for 2013 is maintained.
  • For the first quarter of 2013, Veloxis' research and development costs amounted to DKK 38.9 million compared to DKK 62.8 million during the same period in 2012.
  • On 31 March, 2013, Veloxis had cash and cash equivalents of DKK 456.2 million.

Outlook for 2013
Veloxis maintains its 2013 outlook with an operating and net loss of DKK 170-200 million for the financial year 2013.

As at 31 March 2013, the Company's cash position equaled DKK 456.2 million, and as at 31 December 2013, the Company's cash position is expected to be in the range of DKK 270-310 million.

Conference call
A conference call will be held tomorrow, 16 May, 2013 at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM EDT (New York).

To access the live conference call, please dial one of the following numbers: 
+45 32 72 80 18 (Denmark)
+44 (0) 1452 555 131 (UK)
+1 866 682 8490 (USA)
Access code 64307755

Following the conference call, a recording will be available on the company's website www.veloxis.com.

Research & development update
LCP-Tacro™ in kidney transplant patients
Veloxis has completed one Phase III study and has advanced a second Phase III study of LCP-Tacro™ in kidney transplant recipients as the basis for its development programme for LCP-Tacro™ as a once-daily agent for the prophylaxis of organ rejection in kidney transplantation. The first of these studies, the 3001 Study was a non-inferiority study performed in 326 stable kidney transplant recipients, and was successfully completed in 2011, meeting its primary efficacy and safety endpoints when compared to Prograf® (tacrolimus, Astellas Pharma Inc.). The second study, Study 3002 is being undertaken in de novo kidney transplant recipients. This study is a randomized, double-blind, multicenter study that compares once-daily LCP-Tacro™ against twice-daily Prograf® in de novo adult kidney transplant patients. The primary endpoint of the study, a composite endpoint (biopsy proven acute rejection, graft failure, loss to follow up or death), will be evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro™ compared to Prograf®. Secondary endpoints will include safety, tolerability and renal function assessments. The study completed enrollment in March 2012 of 543 patients at approximately 90 transplant centers, primarily in the U.S. and Europe. Results from this study are expected mid-2013. Patients will participate in a 12-month extension period on treatment for follow-up safety assessments.

In addition to the pivotal Phase III studies, Veloxis is planning a series of Phase IIIb/IV studies to further evaluate potential differences in clinical profile provided by LCP-Tacro's unique PK profile. The first study initiated is the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) study of LCP-Tacro™ in kidney transplant recipients experiencing drug-induced tremors. The STRATO study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard immediate release twice-daily tacrolimus capsules to extended release once-daily LCP-Tacro™ tablets leads to a measurable improvement in tremor. Results from this study are expected to be presented at the American Transplant Congress in Seattle on 19 May, 2013.

LCP-Tacro™ Regulatory Strategy
On 29 April, 2013 a Marketing Authorization Application (MAA) was submitted by Veloxis to the European Medicines Agency seeking approval to market LCP-Tacro™ for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission was based on the favorable results of the LCP-Tacro™ Phase III 3001 Study in stable kidney transplant patients and data from an extensive Phase I and II clinical program. Veloxis expects to receive a decision on the application in 2014.

The U.S. submission for LCP-Tacro™, for the prophylaxis of organ rejection, to the FDA (Food and Drug Administration) is planned for the second half of 2013 and will include data from the 3002 de novo study in addition to data from Phase I, II and Study 3001.

Financial Highlights











Q1

Q1

Year



2013

2012

2012



DKK'000

DKK'000

DKK'000






Income Statement




Revenue

6,868

-

6,868

Research and development costs

(38,947)

(62,848)

(210,739)

Administrative expenses

(7,777)

(10,231)

(36,889)

Operating loss before restructuring cost

(39,856)

(73,079)

(240,760)

Restructuring cost

-

-

(21,462)

Operating loss

(39,856)

(73,079)

(262,222)

Net financial income / (expenses)

3,907

(1,592)

(850)

Loss before tax

(35,949)

(74,671)

(263,072)

Tax for the period

244

(318)

363

Net loss for the period

(35,704)

(74,989)

(262,709)






Balance Sheet




Cash and cash equivalents

456,216

213,786

496,834

Total assets

465,939

235,187

509,271

Share capital

166,057

452,543

165,932

Total equity

377,276

182,545

409,737

Investment in property, plant and equipment

-

91

260






Cash Flow Statement




Cash flow from operating activities

(45,125)

(80,364)

(205,870)

Cash flow from investing activities

-

29,433

169,712

Cash flow from financing activities

48

(1,310)

404,304

Cash and cash equivalents at period end

456,216

213,786

496,834






Financial Ratios




Basic and diluted EPS

(0.02)

(0.17)

(0.43)

Weighted average number of shares

1,659,683,537

452,542,480

607,511,489

Average number of employees (FTEs)

29

55

48

Assets/equity

1.24

1.29

1.24

The interim report is unaudited.

Revenue
For the first quarter of 2013 Veloxis recognized deferred revenue of DKK 6.9 million as revenue compared to no revenue in the same period of 2012. Deferred revenue consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. and is recognized in the income statement on a straight line basis based on planned development periods.

Research and development costs
For the first quarter of 2013, Veloxis' research and development costs amounted to DKK 38.9 million compared to DKK 62.8 million during the same period in 2012. Research and development costs are mainly attributable to the ongoing phase III trial in LCP-Tacro™ (de novo patients, Study 3002). The reduction in cost between the two quarters is mainly related to effect from the executed restructuring and discontinuation of other pipeline activities in May 2012.

Administrative expenses
For the first quarter of 2013, Veloxis' administrative cost amounted to DKK 7.8 million compared to DKK 10.2 million during the same period in 2012. The reduction in cost is attributable to the continued focus of reducing overall cost, combined with the effect of the restructuring and reduction in number of employees that took place in May 2012.

Compensation costs
For the first three months of 2013, a total of DKK 2.9 million was recognized as share-based compensation. The cost is included in R&D and G&A. The comparable cost for 2012 was DKK 1.6 million.

In the first quarter of 2013, a total of 300,000 warrants have been cancelled, a total of 1,250,000 warrants have been exercised at an exercise price of DKK 0.35, and a total of 18,846,300 warrants were granted to Executive Management at a strike price of DKK 0.36, and a total of 1,783,700 warrants at a strike price of DKK 0.36 was granted to Senior Management.

As of 31 March, 2013, there were a total of 104,978,157 warrants outstanding at an average strike price of DKK 0.9. Members of the Board of Directors held 559,011 warrants at an average strike price of DKK 5.1. Members of the Executive Management held 55,300,661 warrants at an average strike price of DKK 0.5, while other current and former employees held 49,118,484 warrants at an average strike price of DKK 1.2.

Please refer to Veloxis' latest annual report for additional details on the Company's warrant programs.

Operating loss
Veloxis' operating loss for the first three months of 2013 was DKK 39.8 million compared to DKK 73.1 million in the corresponding period of 2012.

Financial income
During the first three months of 2013, the Company recognized net financial income of DKK 3.9 million compared to net financial expenses of DKK 1.6 million in the corresponding period of 2012. The income is mainly due to currency gain following the increase in the USD / DKK currency rate during the first quarter of 2013.

Net loss 
Veloxis' net loss for the first three months of 2013 was DKK 35.7 million compared to DKK 75.0 million in the corresponding period of 2012.

Cash flow
As per 31 March, 2013, the balance sheet reflects cash and cash equivalents of DKK 456.2 million compared to DKK 496.8 million as per 31 December, 2012. This represents a decrease of DKK 40.6 million primarily related to the Company's operating activities for the period.

Balance sheet
As per 31 March, 2013, total assets were DKK 465.9 million compared to DKK 509.3 million at the end of 2012.

Shareholders' equity equalled DKK 377.3 million as of 31 March, 2013, compared to DKK 409.7 million at the end of 2012.

For more information, please contact:


John D. Weinberg                                     

Johnny Stilou

EVP, Chief Commercial Officer                   

EVP, Chief Financial Officer

Mobile: +1 908 304 3389                             

Mobile: +45 21 227 227

Email: jdw@veloxis.com                             

Email: jst@veloxis.com

The forward looking statements and targets contained herein are based on the current view and assumptions of the Executive Management and the Board of Directors of Veloxis Pharmaceuticals A/S. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Veloxis Pharmaceuticals A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless  required by applicable law.

About LCP‐Tacro™ and tacrolimus
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after transplantation. LCP-Tacro™ is an investigational drug that is being developed as a once-daily tablet version of tacrolimus with improved bioavailability, consistent pharmacokinetic performance and reduced peak-to-trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

About Veloxis Pharmaceuticals
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro™ for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit http://www.veloxis.com.

Executive Management's and the Board of Directors' Statement on the Interim Report

The Executive Management and the Board of Directors have considered and adopted the Interim Report of Veloxis Pharmaceuticals A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces.

 

Horsholm, 15 May, 2013

 

Executive Management



Dr. William J. Polvino                    

Johnny Stilou

President & CEO                          

Executive Vice President & CFO                          



Board of Directors



Kim Bjornstrup                             

Thomas Dyrberg                                                      

(Chairman)                                    

(Deputy Chairman)



Anders Gotzsche                          

Mette Kirstine Agger                                              

 


Financial Highlights







Quarterly Numbers in DKK

















Q1


Q4

Q3

Q2

Q1



2013


2012

2012

2012

2012



DKK'000


DKK'000

DKK'000

DKK'000

DKK'000









Income Statement







Revenue

6,868


6,868

-

-

-

Research and development costs

(38,947)


(41,890)

(49,362)

(56,639)

(62,848)

Administrative expenses

(7,777)


(10,235)

(6,961)

(9,462)

(10,231)

Operating loss before restructuring cost

(39,856)


(45,257)

(56,323)

(66,101)

(73,079)

Restructuring cost

-


-

-

(21,462)

-

Operating loss

(39,856)


(45,257)

(56,323)

(87,563)

(73,079)

Net financial income / (expenses)

3,907


(2,302)

993

2,051

(1,592)

Loss before tax

(35,949)


(47,559)

(55,330)

(85,512)

(74,671)

Tax for the period

244


1,034

(223)

(130)

(318)

Net loss for the period

(35,704)


(46,525)

(55,553)

(85,642)

(74,989)









Balance Sheet







Cash and cash equivalents

456,216


496,834

86,683

152,720

213,786

Total assets

465,939


509,271

99,590

167,799

235,187

Share capital

166,057


165,932

45,254

45,254

452,543

Total equity

377,276


409,737

42,103

98,968

182,545

Investment in property, plant and equipment

-


43

-

126

91









Cash Flow Statement







Cash flow from operating activities

(45,125)


(399)

(62,707)

(62,400)

(80,364)

Cash flow from investing activities

-


56,619

59,486

24,174

29,433

Cash flow from financing activities

48


410,149

(3,450)

(1,085)

(1,310)

Cash and cash equivalents at period end

456,216


496,834

86,683

152,720

213,786









Financial Ratios







Basic and diluted EPS

(0.02)


(0.08)

(0.12)

(0.19)

(0.17)

Weighted average number of shares

1,659,683,537


607,511,489

452,542,480

452,542,480

452,542,480

Average number of employees (FTEs)

29


33

49

55

55

Assets/equity

1.24


1.24

2.37

1.70

1.29

 

 


Income statement and statement of comprehensive income


Income Statement

Consolidated






(DKK'000)

Q1

Q1

Year



2013

2012

2012






Revenue

6,868

-

6,868

Research and development costs

(38,947)

(62,848)

(210,739)

Administrative expenses

(7,777)

(10,231)

(36,889)






Operating loss before restructuring cost

(39,856)

(73,079)

(240,760)






Restructuring cost

-

-

(21,462)






Operating loss

(39,856)

(73,079)

(262,222)






Financial income

8,872

1,577

1,481

Financial expenses

(4,965)

(3,169)

(2,331)






Loss before tax

(35,949)

(74,671)

(263,072)






Tax for the period

244

(318)

363






Net loss for the period

(35,704)

(74,989)

(262,709)





















Basic and diluted EPS

(0.02)

(0.17)

(0.43)






Weighted average number of shares

1,659,683,537

452,542,480

607,511,489





















Statements of comprehensive income

Consolidated






(DKK'000)

Q1

Q1

Year



2013

2012

2012






Net loss for the period

(35,704)

(74,989)

(262,709)

  Other comprehensive income:




  Currency translation differences

(128)

74

427






  Other comprehensive income for the period

(128)

74

427






Total comprehensive income for the period

(35,832)

(74,915)

(262,282)

 

 


Balance sheet


Assets




Consolidated











(DKK'000)


31 Mar.


31 Mar.


31 Dec.




2013


2012


2012









Patent rights and software


2,103


2,591


2,225









Intangible assets


2,103


2,591


2,225

















Property, plant and equipment


2,814


8,334


2,994

Leasehold improvements


79


3,327


115









Property, plant and equipment


2,893


11,661


3,109









Non-current assets


4,996


14,252


5,334

















Other receivables


3,267


5,325


5,181

Prepayments


1,460


1,824


1,922









Receivables


4,727


7,149


7,103









Securities


-


137,273


-

Cash


456,216


76,513


496,834









Cash and cash equivalents


456,216


213,786


496,834









Current assets


460,943


220,935


503,937









Assets


465,939


235,187


509,271

 

 


Balance sheet


Equity & Liabilities




Consolidated











(DKK'000)


31 Mar.


31 Mar.


31 Dec.




2013


2012


2012









Share capital


166,057


452,543


165,932

Special reserve


407,289


-


407,289

Translation reserves


2,230


2,005


2,358

Retained earnings/loss


(198,300)


(272,003)


(165,842)









Equity


377,276


182,545


409,737









Finance lease


-


2,698


-









Non-current liabilities


-


2,698


-









Finance lease


3,275


4,318


3,665

Trade payables


20,448


20,346


18,590

Deferred revenue


41,208


-


48,076

Other payables


23,732


25,280


29,203









Current liabilities


88,663


49,944


99,534









Liabilities


88,663


52,642


99,534









Equity and liabilities


465,939


235,187


509,271

 

 


Cash flow statements



Cash Flow Statement

Consolidated






(DKK'000)

Q1

Q1

Year



2013

2012

2012






Operating loss

(39,856)

(73,079)

(262,222)






Share-based payment

2,933

1,560

7,154

Depreciation and amortization

340

1,240

3,391

Impairment loss

-

-

6,141

Net gain on sale of fixed assets

-

-

(2,375)

Changes in working capital

(8,504)

(10,127)

42,601






Cash flow from operating activities before interest

(45,087)

(80,406)

(205,310)






Interest received

48

482

1,481

Interest paid

(18)

(122)

(568)

Corporate tax paid

(68)

(318)

(1,473)






Cash flow from operating activities

(45,125)

(80,364)

(205,870)











Purchase of property, plant and equipment

-

(91)

(260)

Sale of property, plant and equipment

-

-

3,175

Investments in securities

-

(3,761)

(19,909)

Sale of securities

-

33,285

186,706






Cash flow from investing activities

-

29,433

169,712











Installments on bank borrowings and finance lease

(389)

(1,310)

(4,662)

Proceeds from issuance of shares, net

437

-

408,966






Cash flow from financing activities

48

(1,310)

404,304











Increase/(decrease) in cash

(45,077)

(52,241)

368,146

Cash at beginning of period

496,834

130,930

130,930

Exchange gains/(losses) on cash

4,459

(2,176)

(2,242)






Cash at end of period

456,216

76,513

496,834











Cash and cash equivalents at end of period comprise:









Securities

-

137,273

-

Deposit on demand and cash

456,216

76,513

496,834








456,216

213,786

496,834

 

 

Statement of changes in equity




Consolidated Equity











Number of

 Shares


Share

Capital

Share

 Premium

Special

 Reserves

Translation

 Reserves

Retained

 Earnings

Total





DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000











Equity as of 1 January 2012

452,542,480


452,543

-


1,931

(198,574)

255,900











Total comprehensive income






74

(74,989)

(74,915)











Share-based payment







1,560

1,560











Equity as of 31 March 2012

452,542,480


452,543

-

-

2,005

(272,003)

182,545











Total comprehensive income






353

(187,720)

(187,367)











Reduction of share capital



(407,289)


407,289



-

Issuance of shares

1,206,779,946


120,678

301,695




422,373

Share-based payment







5,594

5,594

Costs related to capital increases




(13,408)




(13,408)

Transfer of retained earnings




(288,287)



288,287

-











Equity as of 31 December 2012

1,659,322,426


165,932

-

407,289

2,358

(165,842)

409,737











Total comprehensive income






(128)

(35,704)

(35,832)











Warrant exercises

1,250,000


125

313




438

Share-based payment







2,933

2,933

Transfer of retained earnings




(313)



313

-











Equity as of 31 March 2013

1,660,572,426


166,057

-

407,289

2,230

(198,300)

377,276

 

Notes

1.    Accounting policies 
The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of Veloxis Pharmaceuticals' annual report for 2012.

 

SOURCE Veloxis Pharmaceuticals



RELATED LINKS
http://www.veloxis.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.